Return to search results.
Complete title: A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer
|Research Study Number||20122057|
|Principal Investigator||Robert Montgomery, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Genitourinary Cancer; Prostate Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.